How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?

Supportive Care in Cancer

Volumn 19, Issue 10, 2011, Pages 1667-1674

  Chan, Alexandre ^a,b   Tan, Eng Hooi ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Dermatological toxicities; Epidermal growth factor receptor inhibitors; Grading scale; MESTT; NCI CTCAE; Tyrosine kinase inhibitors

Indexed keywords

ERLOTINIB; GEFITINIB; LAPATINIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB;

ADULT; ALOPECIA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; DRUG ERUPTION; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MASCC EGFRI SKIN TOXICITY TOOL; NAIL DISEASE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NATIONAL CANCER INSTITUTE COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS; PARONYCHIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; SINGAPORE; SKIN TOXICITY; XEROSIS;

EID: 84984570566     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-010-0999-2     Document Type: Article

References (18)

1. OSI P (2008) Tarceva® (Erlotinib) [package insert]. In Edition Melville, NY: Genentech
2. AstraZeneca (2005) Iressa® (Gefitinib) [package insert]. In Edition Wilmington, DE
3. GlaxoSmithKline (2008) Tykerb® (Lapatinib) [package insert]. In Edition Research Triangle Park, NC
4. Bayer HPI (2009) Nexavar® (Sorafenib) [package insert]. In Edition Wayne, NJ
5. Pfizer I (2008) Sutent® (Sunitinib) [package insert]. In Edition New York, NY
6. L Chou J Garey K Oishi E Kim 2007 Managing dermatologic toxicities of epidermal growth factor receptor inhibitors Clin Lung Cancer 8 S15 S22 10.3816/CLC.2006.s.009
7. R Perez-Soler JP Delord A Halpern, et al. 2005 HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum Oncologist 10 345 356 15851793 10.1634/theoncologist.10-5-345 1:CAS:528:DC%2BD2MXltVWhs7g%3D (Pubitemid 40647253)
8. TJ Lynch Jr ES Kim B Eaby, et al. 2007 Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management Oncologist 12 610 621 17522250 10.1634/theoncologist.12-5-610 1:CAS:528:DC%2BD2sXntVynsLw%3D (Pubitemid 350012125)
9. B Melosky R Burkes D Rayson, et al. 2009 Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations Curr Oncol 16 14 24 10.3747/co.v16i1.361
10. National Cancer Institute (2009) Common terminology criteria for adverse events v4.0 In Edition 2009
11. Lacouture ME, Maitland ML, Segaert S et al (2009) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Supportive Care in Cancer, 1-14
12. EH Tan A Chan 2009 Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors Ann Pharmacother 43 1658 1666 19755624 10.1345/aph.1M241 1:CAS:528: DC%2BC3cXmtlWns74%3D
13. Wolf SE (2009) Burns. In the merck manuals online medical library, Edition 2009
14. Walters SJ (2009) Quality of life outcomes in clinical trials and health-care evaluation: a practical guide to analysis and interpretation. Wiley, West Sussex
15. A Wollenberg N Moosmann E Klein K Katzer 2008 A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition Exp Dermatol 17 790 792 18503553 10.1111/j.1600-0625.2008.00715.x
16. ME Lacouture S Basti J Patel A Benson 2006 The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors J Support Oncol 4 236 238 16724647
17. C Gridelli P Maione D Amoroso, et al. 2008 Clinical significance and treatment of skin rash from erlotinib in non-small cell lung cancer patients: results of an experts panel meeting Crit Rev Oncol Hematol 66 155 162 18083041 10.1016/j.critrevonc.2007.10.004 1:STN:280:DC%2BD1c3islWlug%3D%3D
18. A Tejwani S Wu Y Jia, et al. 2009 Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy Cancer 115 1286 1299 19170238 10.1002/cncr.24120 1:CAS:528:DC%2BD1MXktlKnsLw%3D